Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on April 23, 2025, and April 24, 2025. The registrant, formerly known as Organovo Holdings, Inc., officially changed its corporate name to VivoSim Labs, Inc. effective April 24, 2025. The company is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Key Financial Metrics
This filing is a current report regarding corporate governance and strategic rebranding. It does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. No financial performance data is provided in this document.
Material Changes
- Corporate Name Change: The company changed its name from Organovo Holdings, Inc. to VivoSim Labs, Inc. via a Certificate of Fourth Amendment to its Certificate of Incorporation.
- Bylaws Amendment: The company amended and restated its Bylaws to reflect the new name. No other changes to the Bylaws were made.
- Stock Ticker Symbol: Effective April 24, 2025, the common stock began trading on the Nasdaq Capital Market under the new ticker symbol "VIVS". The CUSIP number (68620A302) remains unchanged.
- Strategic Pivot: The company announced its emergence from "stealth mode" to provide technologies aimed at facilitating FDA approval processes by moving away from animal models.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights a strategic shift toward technologies that support regulatory pathways by reducing reliance on animal models. This announcement was made via a press release furnished as Exhibit 99.1.
Risks and Contingencies: The filing states that the name change does not affect stockholder rights. No specific financial risks, contingencies, or forward-looking guidance regarding revenue or earnings are detailed in this specific 8-K document.
Investor Verification Checklist
- Verify the new ticker symbol VIVS on the Nasdaq Capital Market for trading purposes.
- Confirm the CUSIP number remains 68620A302 for record-keeping and settlement.
- Review the attached press release (Exhibit 99.1) for specific details on the new technology platform and "stealth mode" exit strategy.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.